Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	S26-S34
Journal	Diabetes research and clinical practice
Volume	86
DOIs	https://doi.org/10.1016/S0168-8227(09)70006-3
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{144a2da842cb4351a4bf06169acc4d9f,

title = "Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide",

author = "\{van Genugten\}, R.E. and \{van Raalte\}, D.H. and M. Diamant",

year = "2009",

doi = "10.1016/S0168-8227(09)70006-3",

language = "English",

volume = "86",

pages = "S26--S34",

journal = "Diabetes research and clinical practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

AU - van Genugten, R.E.

AU - van Raalte, D.H.

AU - Diamant, M.

PY - 2009

Y1 - 2009

U2 - 10.1016/S0168-8227(09)70006-3

DO - 10.1016/S0168-8227(09)70006-3

M3 - Article

SN - 0168-8227

VL - 86

SP - S26-S34

JO - Diabetes research and clinical practice

JF - Diabetes research and clinical practice

ER -